Research programme: gastrointestinal motility therapeutics - Solvay/Mayo
Latest Information Update: 11 Jul 2007
Price :
$50 *
At a glance
- Originator Mayo Clinic; Solvay Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 11 Jul 2007 Discontinued - Preclinical for Gastrointestinal disorders in USA (unspecified route)
- 04 Aug 2005 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)